Tivantinib
| Key | Value |
|---|---|
| Synonyms: | 905854-02-6 ARQ 197 ARQ-197 ARQ197 TIVANTINIB A-1109 (-)-3(R)-(5,6-DIHYDRO-4H-PYRROLO[3,2,1-IJ]QUINOLIN-1-YL)... 758242 |
| National Service Center# (NSC#):1,2 | 758242 |
| CAS#: | 1000873982 |
| PubChem Substance#: | 440812818 |
| PubChem Compound#: | 11494412 |
| Mechanism of Action: | PK:YK,MET |
| Status: | Clinical trial |
| Molecular Formula: | C23H19N3O2 |
| Smiles: | O=C1NC(=O)[C@H]([C@@H]1c2c[nH]c3ccccc23)c4cn5CCCc6cccc4c56 |
Tivantinib is in CellMinerCDB, a searchable tool integrating cancer cell line pharmacogenomics data to link gene and drug activity signatures.
Click Here to Access CellMinerCDB
Tivantinib is in CellMiner (NCI-60),a database and query tool designed for the cancer research community to facilitate integration and study of molecular and pharmacological data for the NCI-60 cancerous cell lines.
Click Here to Access CellMiner (NCI-60)
If you use content from this page, CellMinerCDB or CellMiner (NCI-60), please cite: Luna A et al. 2021. PMID: 33196823, Rajapakse VN et al. 2018. PMID: 30553813, Luna et al. 2016., PMID: 26635141, and Reinhold et al. 2012., PMID: 22802077.
Available Data
Visit CellMinerCDB to interactively explore available pharmacogenomics data for Tivantinib.
Visit CellMiner (NCI-60) to explore NCI-60 related analysis for Tivantinib.
| NCI60 | HTS384 NCI60 | GDSC-MGH-Sanger | GDSC1 drugs | GDSC2 drugs | CCLE-Broad-MIT | CTRP-Broad-MIT | NCI-DTP SCLC | PRISM-Broad-MIT | NCI60-DTP Almanac | NCATS IC50 | NCATS AUC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 758242 | 758242 | NA | NA | NA | NA | tivantinib | 758242 | tivantinib | NA | tivantinib | tivantinib |
2 Most structures have a unique NSC number but over the years a small percentage of structures or agents may have been assigned more than one NSC number. In the case of salts, different salt forms (e.g. HCl, HOAc) are designated with separate NSC numbers.
